Clinical trials
Brain Tumor Adult clinical trials
Below are recruiting brain tumor adult clinical trials, each written for real people, not researchers. We’re tracking 169 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT06231186Recruiting
Study of iHD-SRT for brain metastases
This study tests a new type of radiation therapy (iHD-SRT) for people with brain metastases. It aims to see if this approach is safe and effective for treating tumors that have spread to the brain.
Shanghai, Shanghai MunicipalityAges Any age - NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for new glioblastoma
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
Miami, FloridaAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT03028246Recruiting
Safety study using focused ultrasound for certain brain tumors
This study tests whether a focused ultrasound treatment is safe for children and young adults who have a non-cancerous (benign) tumor in the center of the brain. It mainly checks safety, and it also includes monitoring before and during treatment to reduce risks like bleeding or imaging-related problems.
Washington D.C., District of ColumbiaAges 5–22 - NCT07455136Recruiting
Blood test for traumatic brain injury diagnosis and monitoring
This study is testing a new blood-based test to help doctors diagnose traumatic brain injury (TBI) and track recovery or complications. If you have had a head injury and a CT scan as part of your care, you may be able to join.
Sacramento, CaliforniaAges 18 years+ - NCT07222267RecruitingPhase 1
Study of BG-75202 for advanced solid tumors
This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.
Birmingham, AlabamaAges 18 years+ - NCT06378593RecruitingPhase 1/Phase 2
Study of drug 3HP-2827 for tumors with FGFR2 changes
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04686682RecruitingPhase 1/Phase 2
Study drug for adults with advanced cancers or AML
This early study (Phase 1/2) tests a new medicine (JAB-8263) in adults with advanced solid tumors or recurrent/refractory AML. It aims to find a safe dose and see whether it can shrink tumors or control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03067181RecruitingPhase 3
Active surveillance and chemotherapy for germ cell tumors
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
Birmingham, AlabamaAges Any age - NCT05872204RecruitingPhase 2
Abemaciclib plus letrozole for rare ER-positive ovarian cancer
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Liège, LiègeAges 18 years+ - NCT06399757RecruitingPhase 1/Phase 2
A study of APL-5125 for advanced solid tumors
This trial tests a new drug called APL-5125 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. If you have certain types of advanced cancer, this study may offer a new option.
Duarte, CaliforniaAges 18 years+ - NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Phoenix, ArizonaAges 18–70 - NCT07025070Recruiting
Exercise and brain health in active vs. inactive adults
This study looks at how physical activity affects brain health in healthy adults. It compares people who exercise regularly with those who are not very active, to see if staying active helps keep the brain sharp.
Madrid, MadridAges 40–75 - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This trial tests an experimental drug called rilvegostomig, given as a shot under the skin, for people with advanced solid tumors that have spread or can't be removed and have already had standard treatments. The study checks how the body processes the drug and its safety.
Huntersville, North CarolinaAges 18 years+ - NCT07438782RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05943756Recruiting
Well-being program for adults living with moderate to severe brain injury
This trial tests whether a well-being program can improve quality of life in adults with moderate to severe traumatic brain injury (TBI) more than a year after the injury. If you meet the language and medical-history requirements, you may be invited to join and complete program sessions and screening.
East Hanover, New JerseyAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06270706RecruitingPhase 1
Study of a new drug for advanced solid tumors after immunotherapy
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
New Haven, ConnecticutAges 18 years+ - NCT06770764RecruitingPhase 1
Testing ODC-IL2 for advanced solid tumors
This trial tests a new drug called ODC-IL2 for people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help your immune system fight cancer. The study starts with small doses to find the best dose, then expands to see how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT07135791Recruiting
Tracking daily fatigue in adults with brain injury or cerebral palsy
This study uses a smartphone app to track how fatigue changes throughout the day in adults with cerebral palsy or acquired brain injury. The goal is to better understand fatigue patterns so doctors can offer better support.
Glostrup MunicipalityAges 30–65
Hear when a new Brain Tumor Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain tumor adult?
- Yes. Clin2 currently lists 169 recruiting brain tumor adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain tumor adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain tumor adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.